Jin Medical International Ltd. Files 2024 Annual Report

Ticker: ZJYL · Form: 20-F · Filed: Jan 24, 2025 · CIK: 1837821

Jin Medical International Ltd. 20-F Filing Summary
FieldDetail
CompanyJin Medical International Ltd. (ZJYL)
Form Type20-F
Filed DateJan 24, 2025
Risk Levelmedium
Pages15
Reading Time19 min
Key Dollar Amounts$0.001, $0.00005, $50,000, $1.3 million
Sentimentneutral

Sentiment: neutral

Topics: annual-report, 20-f, sec-filing

TL;DR

Jin Medical filed its 2024 20-F, check financials for the ortho/surgical supply company.

AI Summary

Jin Medical International Ltd. filed its annual report on Form 20-F for the fiscal year ended September 30, 2024. The company, incorporated in E9 and headquartered in Changzhou City, Jiangsu Province, operates in the orthopedic, prosthetic, and surgical appliances and supplies industry. The filing was made on January 24, 2025, under SEC file number 001-41661.

Why It Matters

This filing provides investors with the company's financial performance and operational details for the fiscal year 2024, crucial for understanding its current standing and future prospects.

Risk Assessment

Risk Level: medium — As a foreign private issuer filing an annual report, there's inherent risk in understanding the company's operations and financial reporting standards compared to domestic US companies.

Key Numbers

  • 20240930 — Fiscal Year End (The period covered by the annual report.)
  • 20250124 — Filing Date (The date the annual report was submitted to the SEC.)

Key Players & Entities

  • Jin Medical International Ltd. (company) — Filer of the 20-F
  • 0001213900-25-006519 (dollar_amount) — Accession Number for the filing
  • 20250124 (dollar_amount) — Filing date
  • 20240930 (dollar_amount) — Fiscal year end date
  • 001-41661 (dollar_amount) — SEC file number
  • 3842 (dollar_amount) — Standard Industrial Classification code

FAQ

What is the primary business of Jin Medical International Ltd. as indicated by its SIC code?

Jin Medical International Ltd.'s primary business is in the 'ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES' industry, as indicated by its SIC code 3842.

What is the SEC file number for Jin Medical International Ltd.?

The SEC file number for Jin Medical International Ltd. is 001-41661.

When did the fiscal year covered by this 20-F filing end?

The fiscal year covered by this 20-F filing ended on September 30, 2024.

Where is Jin Medical International Ltd. headquartered?

Jin Medical International Ltd. is headquartered at NO. 33 LINGXIANG ROAD, WUJIN DISTRICT, CHANGZHOU CITY, JIANGSU PROVINCE, China.

What type of SEC filing is this document?

This document is an Annual Report on Form 20-F.

Filing Stats: 4,631 words · 19 min read · ~15 pages · Grade level 14.4 · Accepted 2025-01-24 16:10:41

Key Financial Figures

  • $0.001 — registered Ordinary shares, par value $0.001 per share ZJYL The Nasdaq Stock Market
  • $0.00005 — ) ordinary shares with a par value of US$0.00005 each (the "Subdivision"), such that, fo
  • $50,000 — rized share capital of the Company is US$50,000 divided into 1,000,000,000 shares with
  • $1.3 million — red cash in the amount of approximately $1.3 million to Anhui Zhongjin, our wholly owned sub

Filing Documents

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 136 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 136 PART II 137 ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 137 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 137 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 137 ITEM 16 [Reserved] 138 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 138 ITEM 16B. CODE OF ETHICS 138 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 138 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 138 ITEM 16E PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 138 ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 138 ITEM 16G. CORPORATE GOVERNANCE 140 ITEM 16H. MINE SAFETY DISCLOSURE 140 ITEM 16I DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 140 ITEM 16J INSIDER TRADING POLICIES 140 ITEM 16K CYBERSECURITY 140 PART III 141 ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 141 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 141 ITEM 19. EXHIBITS 141 i INTRODUCTION Unless otherwise indicated, numerical figures included in this Annual Report on Form 20-F (the "Annual Report") have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. For the sake of clarity, this Annual Report follows the English naming convention of first name followed by last name, regardless of whether an individual's name is Chinese or English. Numerical figures included in this Annual Report have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. Certain market data and other statistical information contained in this Annual Report are based on information from independent industry organizations, publications, surveys and forecasts. Some market data and statistical information contained in this Annual Report are also based on management's estimates and calculations, which are derived from our review and interpretation of the independent sources listed above, our internal research and our knowledge of the PRC information technology industry. While we believe such information is reliable, we have not independently verified any third-party information and our internal data has not been verified by any independent source. Except where the context otherwise requires and for purposes of this Annual Report on Form 20-F only, references to: "Affiliated Entities" are to our subsidiaries and Changzhou Zhongjin, the VIE in Changzhou City, Jiangsu Province, China and its subsidiaries; "Changzhou Zhongjin" are to Changzhou Zhongjin Medical Equipment Co., Ltd., a company limited by share organized under the laws of the PRC, which we control via a series of contractual arrangements among WFOE, Changzhou Zhongjin and shareholders of Changzhou Zhongjin; "China" o

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS Not applicable.

OFFER STATISTICS AND EXPECTED TIMETABLE

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE Not applicable.

KEY INFORMATION

ITEM 3. KEY INFORMATION Our Holding Company Structure and Risks Related to Doing Business in China Jin Med is a holding company incorporated in the Cayman Islands with no material operations of its own. Our operations are conducted in China by a variable interest entity ("VIE"), Changzhou Zhongjin Medical Equipment Co. Ltd. (Changzhou Zhongjin), and its subsidiaries. We do not have any equity ownership of the VIE. Instead, we control and receive the economic benefits of the VIE's business operations through contractual arrangements, or "VIE Agreements and we consolidate the VIE for accounting purpose only because we met the conditions under the United States generally accepted accounting principles, or U.S. GAAP, to consolidate the VIE. The VIE agreements are used to provide contractual exposure to foreign investment in China-based companies where Chinese law prohibits direct foreign investment in Chinese operating companies. The Ordinary Shares of Jin Med are shares of our Cayman Islands holding company, not shares of the VIE. Investors of our Ordinary Shares will not own any equity interests in the VIE, but instead will own shares of a Cayman Islands holding company. A VIE is an entity that has a total equity investment that is insufficient to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, the right to receive the expected residual returns of the entity, or the obligation to absorb the expected losses of the entity. Under U.S. GAAP, the Company is deemed to have a controlling financial interest in, and be the primary beneficiary of, the VIE for accounting purposes, because pursuant to the VIE Agreements, the VIE shall pay service fees equal to all of its net profit after tax payments to our wholly owned subsidiary, Erhua Medical Technology (Changzhou) Co., Ltd. ("Erhua Med", or "WFOE"), while WFOE has the power to d

View Full Filing

View this 20-F filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.